Table 3.
Adherence* to DAAs among OAT patients in Norway between 2013 and 2017
| Adherent | Non-adherent | Total | |
| Adherence by gender, n (%) | |||
| Male | 551 (67) | 277 (33) | 828 |
| Female | 191 (67) | 92 (33) | 283 |
| Total | 742 (67) | 369 (33) | 1111 |
| Adherence by age, n (%) | |||
| 18–35 | 119 (58) | 85 (42) | 204 |
| 36–45 | 259 (68) | 122 (32) | 381 |
| 46–55 | 302 (70) | 128 (30) | 430 |
| >56 | 62 (65) | 34 (35) | 95 |
| Total | 742 (67) | 369 (33) | 1111 |
| Adherence by OAT medication, n (%) | |||
| Methadone/levomethadone | 298 (65) | 157 (35) | 455 |
| Buprenorphine based | 444 (68) | 212 (32) | 656 |
| Total | 742 (67) | 369 (33) | 1111 |
| Logistic regression on factors associated with adherence* | |||
| aOR (CI 95%) | P value | ||
| Age | 0.98 (0.97 to 1.00) | 0.17 | |
| Gender | |||
| Male | 1.00 | ||
| Female | 0.92 (0.69 to 1.23) | 0.57 | |
| OAT continuity | |||
| Category I: ≥2 DDD | 1.00 | ||
| Category II: 1–2 DDD | 1.36 (1.02 to 1.82) | 0.035 | |
| Category III: <1 DDD | 1.36 (0.93–1.99) | 0.11 | |
*Adherence defined as collected ≥3 prescriptions and >84 DDDs (unless ledipasvir and sofosbuvir which also calculated as ≥2 prescriptions and >56 DDDs). Analyses included 1111 patients as inclusion were ceased 01.10.17 to avoid counting treatment initiation after this date non-adherent.
DAA, direct-acting antivirals; DDD, daily defined doses; NorPD, Norwegian Prescription Database; OAT, opioid agonist therapy.